Research & Publications: Peer-Reviewed Stem Cell & Exosome Therapy Studies

No. Every study listed here is an independent, peer-reviewed publication sourced from PubMed or PubMed Central. None of it represents SCCI's own clinical trial results — it's provided so you can read the wider scientific evidence behind each treatment area.

Most applications remain investigational under current ICMR guidelines rather than approved cures, and are offered within regulated clinical research and patient-support settings.

A systematic review is a structured survey of all available studies on a question. A meta-analysis goes a step further and statistically pools the numerical results from those studies into a single combined estimate. Most entries on this page are both.

The page is reviewed periodically by our medical team as new systematic reviews and meta-analyses become available on PubMed Central. The "last updated" date at the top reflects the most recent review.

Not on its own. Suitability depends on your specific diagnosis, medical history and reports. Submit your case for a free review and our medical team will advise whether stem cell or exosome therapy may be appropriate for you.

Summaries here are written in our own words to make dense scientific findings easier to read. Each entry links directly to the full, original paper on PubMed Central so you can review the exact methodology, data and conclusions yourself.

Cerebral palsy and Parkinson's disease have the most mature systematic-review evidence in this library. Osteoarthritis has the most recent (2026) publication. The MSC-based immunotherapy meta-analysis for autoimmune and rheumatic immune diseases has the largest pooled patient count (2,183 participants across 42 RCTs), followed by the chronic heart failure meta-analysis (1,684 patients across 17 RCTs). Exosome-based delivery is the earliest-stage, broadest-scope evidence included.

Yes. A 2025 systematic review pooled 11 clinical studies (298 patients) on exosome-based therapy for androgenetic alopecia and other hair loss, finding increased hair density and thickness with a favourable safety profile — see our Exosome Therapy section above and our Hair Loss treatment page.

Yes. A free tele-consultation can be arranged so you can talk through the evidence and how it may or may not relate to your condition, with no obligation to proceed.

Generally no. Because most stem cell applications remain investigational rather than approved treatments in India, insurance typically does not cover the cost. Instalment or financing plans may be available — ask our team for current options.

Every "Read on PubMed Central" link on this page goes directly to the full, freely accessible paper on the U.S. National Library of Medicine's PMC database — including methodology, complete results, and author affiliations.

Call +91 87430 24344 (international) or +91 78382 23336 (India), message on WhatsApp, or use the contact form — a specialist responds within 24–48 hours.

The partner hospital is accredited, and cell processing is carried out in GMP-compliant labs, with a Certificate of Analysis issued per batch.

Stem cell therapy transplants living cells into the body. Exosome therapy instead delivers the tiny signalling particles those cells secrete, without transplanting the cells themselves. The research base for exosomes is newer and generally earlier-stage than for stem cells — see our glossary and the exosome section above.

Autologous means the cells come from the patient's own body; allogeneic means they come from a donor. Several studies on this page specify which approach they tested — for example, the diabetic foot ulcer meta-analysis specifically evaluated autologous cells.

We prioritise systematic reviews and meta-analyses — study designs that pool and critically appraise multiple trials — over single case reports, and we link only to studies indexed on PubMed or PubMed Central so every claim is independently verifiable.

Medical research is presented as-is, including limitations the original authors flagged themselves — such as small sample sizes or non-standardised protocols. We do not omit caveats to make findings sound more definitive than the underlying data supports.

Yes. Submit your medical reports through our contact form or free expert opinion request, and our medical team reviews cases remotely before you commit to travel — see our International Patient Guide for visa, travel and stay logistics.

Most are, but not all — the COPD study currently on this page is preclinical (animal-model) evidence, clearly labelled as such, because no larger pooled human-trial data is yet available for that condition. The chronic kidney disease review combines both preclinical and clinical studies. Always check each card's "Preclinical" or "Clinical" tag before drawing conclusions.

Coverage varies by condition and is assessed case by case based on current evidence and your individual medical reports. Visit the relevant condition treatment page, or contact our medical team to ask about your specific case.

They're related but distinct. This page covers the clinical evidence base, while Exosome Therapy for Retinal Detachment is a condition-specific treatment page for patients dealing with vision loss from a detached retina; the clinical team can advise on how the two fit together.

This page focuses on the clinical evidence base, not on any one condition. For retinal blood-vessel damage, often diabetes-related, see the dedicated Exosome Therapy for Retinopathy page.

It can be. Exosome Therapy for Diabetic Neuropathy is a separate regenerative option some patients researching nerve pain and numbness from diabetes look into alongside the published research behind stem cell therapy, assessed case-by-case during a free medical evaluation.

Some do. Patients reading about the clinical evidence base sometimes also ask about Exosome Therapy for Muscular Dystrophy, since progressive muscle weakness is one area where exosome-based options are considered alongside standard protocols.

They're related but distinct. This page covers the clinical evidence base, while Exosome Therapy for Osteoporosis is a condition-specific treatment page for patients dealing with low bone density and fracture risk; the clinical team can advise on how the two fit together.

This page focuses on the clinical evidence base, not on any one condition. For tremor, rigidity, and movement symptoms, see the dedicated Exosome Therapy for Parkinson’s Disease page.

It can be. Exosome Therapy for Rheumatoid Arthritis is a separate regenerative option some patients researching autoimmune joint inflammation look into alongside the published research behind stem cell therapy, assessed case-by-case during a free medical evaluation.

Some do. Patients reading about the clinical evidence base sometimes also ask about Exosome Therapy for Sciatic Nerve Injury & Sciatica, since sciatic nerve pain radiating down the leg is one area where exosome-based options are considered alongside standard protocols.

They're related but distinct. This page covers the clinical evidence base, while Exosome Therapy for Shoulder Injury is a condition-specific treatment page for patients dealing with rotator cuff and shoulder joint damage; the clinical team can advise on how the two fit together.

This page focuses on the clinical evidence base, not on any one condition. For loss of motor or sensory function after cord damage, see the dedicated Exosome Therapy for Spinal Cord Injury page.

It can be. Exosome Therapy for Spinal Muscular Atrophy is a separate regenerative option some patients researching motor-neuron loss and progressive weakness in SMA look into alongside the published research behind stem cell therapy, assessed case-by-case during a free medical evaluation.

Some do. Patients reading about the clinical evidence base sometimes also ask about Exosome Therapy for Sports Injuries, since soft-tissue and joint injuries from athletic activity is one area where exosome-based options are considered alongside standard protocols.

They're related but distinct. This page covers the clinical evidence base, while Exosome Therapy for Systemic Lupus is a condition-specific treatment page for patients dealing with autoimmune inflammation affecting multiple organs; the clinical team can advise on how the two fit together.

This page focuses on the clinical evidence base, not on any one condition. For slow-healing or chronic wounds, see the dedicated Exosome Therapy for Wound Healing page.